Tertiary lymphoid structures (TLS) are emerging biomarkers for enhanced anti-tumoral immunity and treatment efficacy in colorectal cancer (CRC).
This study aimed to develop a CRC-specific TLS signature and evaluate its predictive roles in survival prognosis and therapeutic responses to chemotherapy; and PD-1 blockade.
